{
    "clinical_study": {
        "@rank": "126160", 
        "arm_group": [
            {
                "arm_group_label": "BAF312 0.5mg", 
                "arm_group_type": "Experimental", 
                "description": "BAF312 0.5 mg/day"
            }, 
            {
                "arm_group_label": "BAF312 2mg", 
                "arm_group_type": "Experimental", 
                "description": "BAF312 2 mg/day"
            }, 
            {
                "arm_group_label": "BAF312 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "BAF312 10 mg/day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study investigates the dose response relationship for the efficacy and safety of BAF312\n      compared to placebo in active DM patients over a treatment period of 6+6 months and to\n      determine the minimum dose required for a maximal clinical effect. The study is composed of\n      2 periods: a double-blind period I with BAF312 administered at different daily doses (0.5,\n      2, 10 mg and placebo) and a fixed-dose Period II in which BAF312 will be administered at the\n      dose of 2 mg daily ."
        }, 
        "brief_title": "Safety and Efficacy of BAF312 in Dermatomyositis", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Active Dermatomyositis", 
        "condition_browse": {
            "mesh_term": "Dermatomyositis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Written informed consent must be obtained before any assessment is performed.\n\n          -  Male and female patients between 18 - 65 (inclusive) years of age who have been\n             defined as \"definite\" or \"probable\" based on the criteria of Bohan and Peter (Bohan\n             and Peter 1975) for dermatomyositis at least 12 months before screening\n\n          -  Patients must have active disease as defined by dermatomyositis skin rash AND Muscle\n             weakness\n\n          -  Patients must have responded inadequately to previous standard of care or have\n             demonstrated significant toxicity or intolerance to such therapies.\n\n          -  Patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily\n             prednisone equivalent)\n\n          -  Patients currently treated with oral or subcutaneous MTX must have been a stable dose\n             of no more/equal to than 25 mg per week\n\n          -  Patients currently treated with Azathioprine must have been a stable maintenance dose\n             of no more/equal to 3 mg/kg/day\n\n          -  Negative cancer screening conducted in the 6 months prior to screening visit\n\n        Exclusion Criteria\n\n          -  Dermatomyositis patients having overlap myositis or any other type of myositis\n             including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis\n\n          -  Preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or\n             significant eye diseases.\n\n          -  Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Other protocol-defined inclusion/exclusion criteria apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029274", 
            "org_study_id": "CBAF312X2206", 
            "secondary_id": "2013-001799-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAF312 0.5mg", 
                "description": "BAF312 0.5 mg once daily", 
                "intervention_name": "BAF312 0.5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAF312 2mg", 
                "description": "BAF312 2 mg once daily", 
                "intervention_name": "BAF312 2 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAF312 10 mg", 
                "description": "BAF312 10 mg once daily", 
                "intervention_name": "BAF312 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo to BAF312 once daily", 
                "intervention_name": "Placebo to BAF312", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Dermatomyositis", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85028"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21224"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Colubus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43221"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3A 2B4"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague 2", 
                        "country": "Czech Republic", 
                        "zip": "128 50"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1083"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary", 
                        "zip": "4032"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba-city", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "260-8712"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawagoe-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "350-8550"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meguro-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "153-8515"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "160-8582"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-461"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland", 
                        "zip": "85-168"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Czech Republic", 
                "Hungary", 
                "Japan", 
                "Poland"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary aim of this study is to assess the efficacy of different doses of BAF312 on the MMT-8 after 6 months. The overall efficacy of BAF312 will be assessed by comparing the improvements of MMT-8 with every dose of BAF312 to that of placebo. Then the doseresponse curve of MMT-8 will be estimated with the aim to determine a target dose for the program.", 
            "measure": "Manual Muscle Testing -8 muscles (MMT-8). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029274"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary variables include the incidence of adverse events.", 
                "measure": "Adverse Events. All information obtained on adverse events will be displayed by treatment (dose group) and subject.", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Secondary variables include plasma BAF312 concentrations.", 
                "measure": "Pharmacokinetics. BAF312 plasma concentration data will be listed by treatment (dose group), subject and visit/sampling time point. Descriptive summary statistics will be provided by treatment and visit/sampling time point.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Secondary variables include peripheral blood lymphocyte counts.", 
                "measure": "Peripheral blood lymphocyte counts. Absolute lymphocyte counts will be plotted against time by dose level.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Changes from baseline in MMT-8 at 3 months will also be evaluated. The dose-response will be assessed in the same way as for the 6-month data.", 
                "measure": "Manual Muscle Testing-8 muscles (MMT-8). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo.", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}